🇺🇸#premarket #сша
премаркет США - акции - заметные движения:
ВВЕРХ
#NAVB +65% Navidea Biopharmaceuticals, Inc. - reported results of second interim analysis of ongoing Phase 2B study in rheumatoid arthritis.
#TTPH +48% Tetraphase Pharmaceuticals, Inc. - announced determination of superior offer from Melinta Therapeutics, Inc.
#SNDL +26% Sundial Growers Inc. - after gaining over 9% on Thursday.
#NTEC +15% Intec Pharma Ltd. - after jumping 23% on Thursday.
#TTOO +15% T2 Biosystems, Inc.
#BLIN +13% Bridgeline Digital, Inc.
#DKL +9% Delek Logistics Partners, LP
#ENTX +8% Entera Bio Ltd. - shares tumbled 27% on Thursday as the company announced interim limited biomarker data from the ongoing Phase 2 clinical trial of EB613 in osteoporosis patients, with the study demonstrating statistically significant effects on the P1NP biomarker after one month of treatment as compared to placebo, and meaningful increases at months two and three as compared to placebo with the highest EB613 dose of 1.5mg.
#ONCY +7% Oncolytics Biotech Inc. -after declining 5% on Thursday.
#PAWN +7% Palo Alto Networks Inc - reported better-than-expected Q3 results. The company also issued FY20 guidance above estimates.
#CNAT +7% Conatus Pharmaceuticals Inc. -after declining 13% on Thursday.
#CLNS +7% Celsion Corporation -after jumping over 36% on Thursday.
#A +5% Agilent Technologies Inc - reported better-than-expected Q2 results.
#BKE +4% Buckle Inc - following Q1 results.
ВНИЗ
#SNDX -20% Syndax Pharmaceuticals, Inc. - reported receipt of final results from Phase 3 E2112 trial of entinostat plus exemestane in patients with HR+, HER2- breast cancer. The trial did not achieve primary endpoint.
#GERN -19% Geron Corporation - announced a proposed public offering of common stock and warrants..
#AKTX -15% Akari Therapeutics, Plc - on Thursday, Akari Therapeutics received positive EMA opinion on orphan designation for nomacopan for bullous pemphigoid.
#PDSB -14% PDS Biotechnology Corporation -after surging 17% on Thursday.
#SONM -13% Sonim Technologies, Inc. - after rising 15% on Thursday.
#XTNT -13% Xtant Medical Holdings, Inc. - after jumping 160% on Thursday.
#HOTH -13% Hoth Therapeutics, Inc. - priced underwritten public offering of 1.8 million shares at $2.75 per share.
#LSCC -12% Lattice Semiconductor Corporation
#CFRX -10% ContraFect Corp - announced a proposed public offering of common stock and warrants.
#IMAB -10% I-Mab - I-Mab and Genexine reported China NMPA clearance for Phase 2 clinical trial of TJ107/HyLeukin-7 in glioblastoma multiforme.
#MPWR -9% Monolithic Power Systems, Inc.
#MXL -9% MaxLinear, Inc. - after dropping over 6% on Thursday.
#DVAX -8% Dynavax Technologies Corporation - announced a proposed public offering of common stock.
#NNDM -6% Nano Dimension Ltd.
#HPE -5% Hewlett Packard Enterprise Co - reported weaker-than-expected Q2 results.
#GDS -5% GDS Holdings Limited - after declining over 5% on Thursday.
премаркет США - акции - заметные движения:
ВВЕРХ
#NAVB +65% Navidea Biopharmaceuticals, Inc. - reported results of second interim analysis of ongoing Phase 2B study in rheumatoid arthritis.
#TTPH +48% Tetraphase Pharmaceuticals, Inc. - announced determination of superior offer from Melinta Therapeutics, Inc.
#SNDL +26% Sundial Growers Inc. - after gaining over 9% on Thursday.
#NTEC +15% Intec Pharma Ltd. - after jumping 23% on Thursday.
#TTOO +15% T2 Biosystems, Inc.
#BLIN +13% Bridgeline Digital, Inc.
#DKL +9% Delek Logistics Partners, LP
#ENTX +8% Entera Bio Ltd. - shares tumbled 27% on Thursday as the company announced interim limited biomarker data from the ongoing Phase 2 clinical trial of EB613 in osteoporosis patients, with the study demonstrating statistically significant effects on the P1NP biomarker after one month of treatment as compared to placebo, and meaningful increases at months two and three as compared to placebo with the highest EB613 dose of 1.5mg.
#ONCY +7% Oncolytics Biotech Inc. -after declining 5% on Thursday.
#PAWN +7% Palo Alto Networks Inc - reported better-than-expected Q3 results. The company also issued FY20 guidance above estimates.
#CNAT +7% Conatus Pharmaceuticals Inc. -after declining 13% on Thursday.
#CLNS +7% Celsion Corporation -after jumping over 36% on Thursday.
#A +5% Agilent Technologies Inc - reported better-than-expected Q2 results.
#BKE +4% Buckle Inc - following Q1 results.
ВНИЗ
#SNDX -20% Syndax Pharmaceuticals, Inc. - reported receipt of final results from Phase 3 E2112 trial of entinostat plus exemestane in patients with HR+, HER2- breast cancer. The trial did not achieve primary endpoint.
#GERN -19% Geron Corporation - announced a proposed public offering of common stock and warrants..
#AKTX -15% Akari Therapeutics, Plc - on Thursday, Akari Therapeutics received positive EMA opinion on orphan designation for nomacopan for bullous pemphigoid.
#PDSB -14% PDS Biotechnology Corporation -after surging 17% on Thursday.
#SONM -13% Sonim Technologies, Inc. - after rising 15% on Thursday.
#XTNT -13% Xtant Medical Holdings, Inc. - after jumping 160% on Thursday.
#HOTH -13% Hoth Therapeutics, Inc. - priced underwritten public offering of 1.8 million shares at $2.75 per share.
#LSCC -12% Lattice Semiconductor Corporation
#CFRX -10% ContraFect Corp - announced a proposed public offering of common stock and warrants.
#IMAB -10% I-Mab - I-Mab and Genexine reported China NMPA clearance for Phase 2 clinical trial of TJ107/HyLeukin-7 in glioblastoma multiforme.
#MPWR -9% Monolithic Power Systems, Inc.
#MXL -9% MaxLinear, Inc. - after dropping over 6% on Thursday.
#DVAX -8% Dynavax Technologies Corporation - announced a proposed public offering of common stock.
#NNDM -6% Nano Dimension Ltd.
#HPE -5% Hewlett Packard Enterprise Co - reported weaker-than-expected Q2 results.
#GDS -5% GDS Holdings Limited - after declining over 5% on Thursday.